Jeremy Bender - Jul 1, 2022 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
Chief Executive Officer, Director
Signature
/s/ Charles N. York II, Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Jul 1, 2022
Transactions value $
-$52,060
Form type
4
Date filed
7/6/2022, 08:56 PM
Previous filing
Jan 20, 2022
Next filing
Jul 12, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Sale -$34.9K -1.75K -0.14% $20.00 1.26M Jul 1, 2022 Direct F1
transaction DAWN Common Stock Sale -$17.1K -857 -0.07% $20.00 1.26M Jul 5, 2022 Direct F1
holding DAWN Common Stock 282K Jul 1, 2022 See Footnote F2
holding DAWN Common Stock 282K Jul 1, 2022 See Footnote F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
F2 Represents shares held by The Jeremy Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person is trustee.
F3 Represents shares held by The Melissa Bender 2022 Grantor Retained Annuity Trust under Irrevocable Trust Agreement dated March 29, 2022 of which the Reporting Person's spouse is trustee.